Bernardo Stefanini

15PUBLICATIONS
55CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 07, 2026
Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores.

|Jan 14, 2026
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study.

Elisa Pinto, Filippo Pelizzaro, Vittorio Simeon

|Sep 22, 2025
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab.

Leonardo Stella, Giuseppe Cabibbo, Ciro Celsa

|Feb 06, 2025
Advancements in immunotherapy for hepatocellular carcinoma.

Sara Ascari, Rusi Chen, Caterina Vivaldi

|Mar 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib.

Bernardo Stefanini, Francesco Tovoli, Franco Trevisani

|Mar 22, 2024
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.

Margherita Rimini, Bernardo Stefanini, Toshifumi Tada

Pageof 3

Frequent Collaborators

8 joint publications

Francesco Tovoli

8 joint publications

Piscaglia Fabio

5 joint publications

Alessandro Granito

4 joint publications

Fabio Marra